A Cytotoxic T Lymphocyte-Inspiring Microscale System for Cancer Immunotherapy
ACS Nano · 2025
DOI: 10.1021/acsnano.4c19012 ↗At a glance
Journal article in ACS Nano, 2025. Written by Fei Wang and 10 co-authors. Institution: The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan 523059, China. Major MEDLINE topics: T-Lymphocytes, Cytotoxic, Immunotherapy, Neoplasms. Cited 6 times so far (Crossref); 76 references. Funded by: National Natural Science Foundation of China, Dongguan Science and Technology of Social Development Program.
Abstract (original language)
Adoptive T cell therapy (ACT) is an emerging cancer immunotherapy undergoing clinical evaluation, showing significant promise in the treatment of solid tumors. However, the clinical translation of ACT is hindered by its time-, labor-, and financial-consuming procedures, heterogeneity of cytotoxic T lymphocytes (CTLs), and immunosuppressive tumor microenvironment. Herein, we have developed a bionic cytotoxic T lymphocyte-inspiring microscale system (CTLiMS) composed of mesoporous silica dioxide microspheres containing membrane-disrupting boron clusters (BICs) and proapoptotic monomethyl auristatin E (MMAE) peptides. The BICs were found to disrupt the integrity of cancer cell membranes and enhance the internalization of MMAE, effectively mimicking the biological functions of perforin and granzymes released by CTLs to destroy cancer cells. As expected, the CTLiMSs demonstrated exceptional in vitro anticancer activity, inducing cancer cell apoptosis and exhibiting strong antiproliferative effects. Notably, CTLiMS treatment was demonstrated to induce immunogenic cell death of cancer cells as a result of Ca2+ and MMAE influx and subsequent production of reactive oxygen species. The animal studies demonstrated that the CTLiMS treatment led to efficient repression of the tumor growth. Furthermore, the CTLiMS administration resulted in favorable antitumor immunotherapeutic effects, as shown by significant inhibition of distant tumors, increased immune cell infiltration, and elevated plasma levels of pro-inflammatory cytokines. This pilot study using CTLiMSs for cancer immunotherapy offers an innovative bionic strategy for the future advancement of adoptive T cell therapy.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan 523059, China.
- Guangdong Provincial Key Laboratory of Cardiac Function and Microcirculation, Guangzhou 510515, China.
- The First School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China.
- The First Clinical College of Jinan University, Guangzhou 510632, China.
ORCID profiles: Zhenhua Li
Funding
- National Natural Science Foundation of China
- Dongguan Science and Technology of Social Development Program
Cite
APA
Wang, F., Li, L., Wang, X., Mo, S., Ai, J., Deng, J., Li, Y., Zhang, Y., Li, Q., Xiao, Y., & Li, Z. (2025). A Cytotoxic T Lymphocyte-Inspiring Microscale System for Cancer Immunotherapy. ACS Nano. https://doi.org/10.1021/acsnano.4c19012
Vancouver
Wang F, Li L, Wang X, Mo S, Ai J, Deng J, et al. A Cytotoxic T Lymphocyte-Inspiring Microscale System for Cancer Immunotherapy. ACS Nano. 2025. doi:10.1021/acsnano.4c19012
BibTeX
@article{Wang2025,
author = {Wang, Fei and Li, Lanya and Wang, Xueyi and Mo, Shushan and Ai, Jiacong and Deng, Junyao and Li, Yimin and Zhang, Yixin and Li, Qishan and Xiao, Yingxian and Li, Zhenhua},
title = {A Cytotoxic T Lymphocyte-Inspiring Microscale System for Cancer Immunotherapy},
journal = {ACS Nano},
year = {2025},
doi = {10.1021/acsnano.4c19012}
}
EUVIMED